

# Ivan Stamenkovic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9845983/publications.pdf>

Version: 2024-02-01

43  
papers

8,968  
citations

147566  
31  
h-index

243296  
44  
g-index

44  
all docs

44  
docs citations

44  
times ranked

13613  
citing authors

#	ARTICLE	IF	CITATIONS
1	Necrotic debris and STING exert therapeutically relevant effects on tumor cholesterol homeostasis. <i>Life Science Alliance</i> , 2022, 5, e202101256.	1.3	2
2	Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia. <i>Cell Death and Disease</i> , 2022, 13, 320.	2.7	5
3	EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma. <i>Nature Communications</i> , 2022, 13, 2267.	5.8	18
4	Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. <i>Nature Medicine</i> , 2021, 27, 289-300.	15.2	64
5	Ewing's Sarcoma. <i>New England Journal of Medicine</i> , 2021, 384, 154-164.	13.9	162
6	A live single-cell reporter assay links intratumor heterogeneity to metastatic proclivity in Ewing sarcoma. <i>Science Advances</i> , 2021, 7, .	4.7	5
7	The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies. <i>Life Science Alliance</i> , 2021, 4, e202000808.	1.3	18
8	Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression. <i>Journal of Pathology</i> , 2020, 250, 555-572.	2.1	107
9	LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma. <i>Cell Reports</i> , 2020, 30, 4567-4583.e5.	2.9	20
10	Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins. <i>Cancer Letters</i> , 2020, 484, 50-64.	3.2	22
11	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	13.5	1,408
12	Reciprocal modulation of mesenchymal stem cells and tumor cells promotes lung cancer metastasis. <i>EBioMedicine</i> , 2018, 29, 128-145.	2.7	50
13	Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 117-140.	9.6	97
14	Epigenome editing of microsatellite repeats defines tumor-specific enhancer functions and dependencies. <i>Genes and Development</i> , 2018, 32, 1008-1019.	2.7	56
15	Synovial sarcoma: when epigenetic changes dictate tumour development. <i>Swiss Medical Weekly</i> , 2018, 148, w14667.	0.8	9
16	Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain. <i>Cell</i> , 2017, 171, 163-178.e19.	13.5	350
17	Tumor-Derived Mesenchymal Stem Cells Use Distinct Mechanisms to Block the Activity of Natural Killer Cell Subsets. <i>Cell Reports</i> , 2017, 20, 2891-2905.	2.9	86
18	The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma. <i>Scientific Reports</i> , 2016, 6, 22113.	1.6	33

#	ARTICLE	IF	CITATIONS
19	IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer. <i>Genes and Development</i> , 2016, 30, 2459-2474.	2.7	214
20	The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing. <i>Cell Reports</i> , 2016, 15, 1634-1647.	2.9	103
21	Recruitment of Matrix Metalloproteinase-9 (MMP-9) to the Fibroblast Cell Surface by Lysyl Hydroxylase 3 (LH3) Triggers Transforming Growth Factor- $\beta^2$ (TGF- $\beta^2$ ) Activation and Fibroblast Differentiation. <i>Journal of Biological Chemistry</i> , 2015, 290, 13763-13778.	1.6	72
22	EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma. <i>Cancer Cell</i> , 2014, 26, 668-681.	7.7	334
23	Targeting Cancer Stem-like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing Sarcoma. <i>Cancer Research</i> , 2014, 74, 6610-6622.	0.4	28
24	Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. <i>Genes and Development</i> , 2012, 26, 1926-1944.	2.7	370
25	A TARBP2-Dependent miRNA Expression Profile Underlies Cancer Stem Cell Properties and Provides Candidate Therapeutic Reagents in Ewing Sarcoma. <i>Cancer Cell</i> , 2012, 21, 807-821.	7.7	89
26	Identification of Prognostic Molecular Features in the Reactive Stroma of Human Breast and Prostate Cancer. <i>PLoS ONE</i> , 2011, 6, e18640.	1.1	140
27	Securin and Separase Modulate Membrane Traffic by Affecting Endosomal Acidification. <i>Traffic</i> , 2011, 12, 615-626.	1.3	24
28	The cancer stem cell paradigm in Ewing's sarcoma: what can we learn about these rare cells from a rare tumor?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 143-145.	1.1	10
29	Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development. <i>PLoS ONE</i> , 2011, 6, e23592.	1.1	77
30	CD44 Attenuates Activation of the Hippo Signaling Pathway and Is a Prime Therapeutic Target for Glioblastoma. <i>Cancer Research</i> , 2010, 70, 2455-2464.	0.4	190
31	EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. <i>Genes and Development</i> , 2010, 24, 916-932.	2.7	254
32	Epigenetic Features of Human Mesenchymal Stem Cells Determine Their Permissiveness for Induction of Relevant Transcriptional Changes by SYT-SSX1. <i>PLoS ONE</i> , 2009, 4, e7904.	1.1	40
33	Identification of Cancer Stem Cells in Ewing's Sarcoma. <i>Cancer Research</i> , 2009, 69, 1776-1781.	0.4	291
34	Shedding Light on Proteolytic Cleavage of CD44: The Responsible Sheddase and Functional Significance of Shedding. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1321-1324.	0.3	48
35	Ewing's sarcoma origin: from duel to duality. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1025-1030.	1.1	35
36	Tumor-host interactions: the role of inflammation. <i>Histochemistry and Cell Biology</i> , 2008, 130, 1079-1090.	0.8	96

#	ARTICLE	IF	CITATIONS
37	EWS-FLI-1 Expression Triggers a Ewing's Sarcoma Initiation Program in Primary Human Mesenchymal Stem Cells. <i>Cancer Research</i> , 2008, 68, 2176-2185.	0.4	293
38	IGF1 Is a Common Target Gene of Ewing's Sarcoma Fusion Proteins in Mesenchymal Progenitor Cells. <i>PLoS ONE</i> , 2008, 3, e2634.	1.1	102
39	The Biology of Ewing sarcoma. <i>Cancer Letters</i> , 2007, 254, 1-10.	3.2	238
40	Development of Ewing's Sarcoma from Primary Bone Marrowâ€Derived Mesenchymal Progenitor Cells. <i>Cancer Research</i> , 2005, 65, 11459-11468.	0.4	326
41	Extracellular matrix remodelling: the role of matrix metalloproteinases. <i>Journal of Pathology</i> , 2003, 200, 448-464.	2.1	929
42	Matrix metalloproteinases in tumor invasion and metastasis. <i>Seminars in Cancer Biology</i> , 2000, 10, 415-433.	4.3	656
43	Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF- $\beta^2$ and promotes tumor invasion and angiogenesis. <i>Genes and Development</i> , 2000, 14, 163-176.	2.7	1,494